Stanford Names Leader for Drug Development and Precision Oncology

1. Dr. Vivek Subbiah appointed as inaugural associate director at Stanford Cancer Institute. 2. He will lead the Early Drug Development Program focusing on phase 1 trials. 3. His expertise lies in tumor-agnostic precision oncology. 4. He has been a principal investigator for over 150 phase I/II trials. 5. Dr. Subbiah aims to enhance access to innovative therapies for patients. 6. He previously led early-phase drug development units at Sarah Cannon Research Institute. 7. Recognized as a leading figure in precision oncology. 8. His work has changed cancer therapeutic strategies significantly.